198 related articles for article (PubMed ID: 25001079)
1. Comparative nonclinical assessments of the proposed biosimilar PF-05280014 and trastuzumab (Herceptin(®)).
Hurst S; Ryan AM; Ng CK; McNally JM; Lorello LG; Finch GL; Leach MW; Ploch SA; Fohey JA; Smolarek TA
BioDrugs; 2014 Oct; 28(5):451-9. PubMed ID: 25001079
[TBL] [Abstract][Full Text] [Related]
2. A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF-05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327-01).
Yin D; Barker KB; Li R; Meng X; Reich SD; Ricart AD; Rudin D; Taylor CT; Zacharchuk CM; Hansson AG
Br J Clin Pharmacol; 2014 Dec; 78(6):1281-90. PubMed ID: 25041377
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin
Chen X; Li C; Ewesuedo R; Yin D
Cancer Chemother Pharmacol; 2019 Jul; 84(1):83-92. PubMed ID: 31053945
[TBL] [Abstract][Full Text] [Related]
4. TROIKA-1: A double-blind, randomized, parallel group, study aimed to demonstrate the equivalent pharmacokinetic profile of HD201, a potential biosimilar candidate to trastuzumab, versus EU-Herceptin
Demarchi M; Coliat P; Mclendon K; Chung Shii Hii J; Feyaerts P; Ang F; Jaison L; Deforce F; Derde MP; Kim MJ; Park LS; Detappe A; Pivot X
Pharmacol Res Perspect; 2021 Aug; 9(4):e00839. PubMed ID: 34309241
[TBL] [Abstract][Full Text] [Related]
5. A phase I pharmacokinetics trial comparing PF-05280586 (a potential biosimilar) and rituximab in patients with active rheumatoid arthritis.
Cohen S; Emery P; Greenwald M; Yin D; Becker JC; Melia LA; Li R; Gumbiner B; Thomas D; Spencer-Green G; Meng X
Br J Clin Pharmacol; 2016 Jul; 82(1):129-38. PubMed ID: 26909489
[TBL] [Abstract][Full Text] [Related]
6. Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade
Derzi M; Johnson TR; Shoieb AM; Conlon HD; Sharpe P; Saati A; Koob S; Bolt MW; Lorello LG; McNally J; Kirchhoff CF; Smolarek TA; Leach MW
Adv Ther; 2016 Nov; 33(11):1964-1982. PubMed ID: 27585978
[TBL] [Abstract][Full Text] [Related]
7. Comparative nonclinical assessments of the biosimilar PF-06410293 and originator adalimumab.
Derzi M; Shoieb AM; Ripp SL; Finch GL; Lorello LG; O'Neil SP; Radi Z; Syed J; Thompson MS; Leach MW
Regul Toxicol Pharmacol; 2020 Apr; 112():104587. PubMed ID: 32006671
[TBL] [Abstract][Full Text] [Related]
8. PF-05280014 (a trastuzumab biosimilar) plus paclitaxel compared with reference trastuzumab plus paclitaxel for HER2-positive metastatic breast cancer: a randomised, double-blind study.
Pegram MD; Bondarenko I; Zorzetto MMC; Hingmire S; Iwase H; Krivorotko PV; Lee KS; Li RK; Pikiel J; Aggarwal R; Ewesuedo R; Freyman A; Li R; Vana A; Yin D; Zacharchuk C; Tan-Chiu E
Br J Cancer; 2019 Jan; 120(2):172-182. PubMed ID: 30568294
[TBL] [Abstract][Full Text] [Related]
9. HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects.
Yang J; Lin L; Long Q; Zhang Q; Sun G; Zhou L; Wang Q; Zhu J; Li F; Hu W
BioDrugs; 2022 May; 36(3):393-409. PubMed ID: 35594017
[TBL] [Abstract][Full Text] [Related]
10. A Randomized Phase I Pharmacokinetic Study Comparing Biosimilar Candidate SB3 and Trastuzumab in Healthy Male Subjects.
Pivot X; Curtit E; Lee YJ; Golor G; Gauliard A; Shin D; Kim Y; Kim H; Fuhr R
Clin Ther; 2016 Jul; 38(7):1665-1673.e3. PubMed ID: 27368117
[TBL] [Abstract][Full Text] [Related]
11. Comparative nonclinical assessments of the proposed biosimilar PF-05280586 and rituximab (MabThera®).
Ryan AM; Sokolowski SA; Ng CK; Shirai N; Collinge M; Shen AC; Arrington J; Radi Z; Cummings TR; Ploch SA; Stephenson SA; Tripathi NK; Hurst SI; Finch GL; Leach MW
Toxicol Pathol; 2014 Oct; 42(7):1069-81. PubMed ID: 24604381
[TBL] [Abstract][Full Text] [Related]
12. A phase I pharmacokinetics study comparing PF-06439535 (a potential biosimilar) with bevacizumab in healthy male volunteers.
Knight B; Rassam D; Liao S; Ewesuedo R
Cancer Chemother Pharmacol; 2016 Apr; 77(4):839-46. PubMed ID: 26984210
[TBL] [Abstract][Full Text] [Related]
13. A Randomized Phase I Study Comparing the Pharmacokinetics of HD201, a Trastuzumab Biosimilar, With European Union-sourced Herceptin.
Pivot X; Deslypere JP; Park LS; Kim MJ; Lee W; Lee J
Clin Ther; 2018 Mar; 40(3):396-405.e4. PubMed ID: 29502805
[TBL] [Abstract][Full Text] [Related]
14. A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL-1401O vs. EU-trastuzumab and US-trastuzumab.
Waller CF; Vutikullird A; Lawrence TE; Shaw A; Liu MS; Baczkowski M; Sharma R; Barve A; Goyal P; Donnelly C; Sengupta N; Pennella EJ
Br J Clin Pharmacol; 2018 Oct; 84(10):2336-2343. PubMed ID: 29926514
[TBL] [Abstract][Full Text] [Related]
15. A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjects.
Hanes V; Chow V; Zhang N; Markus R
Cancer Chemother Pharmacol; 2017 May; 79(5):881-888. PubMed ID: 28341959
[TBL] [Abstract][Full Text] [Related]
16. Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumab.
Peraza MA; Rule KE; Shiue MHI; Finch GL; Thibault S; Brown PR; Clarke DW; Leach MW
Regul Toxicol Pharmacol; 2018 Jun; 95():236-243. PubMed ID: 29574193
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase I study comparing the pharmacokinetics of a bevacizumab (HD204) biosimilar to European Union- and United States of America-sourced bevacizumab.
Demarchi M; Coliat P; Barthelemy P; Schott R; BenAbdelghani M; Kim M; Hii JCS; Feyaerts P; Ang FRX; Derde MP; Deforce F; Petit T; Schwabe C; Wynne C; Park LS; Pivot X
PLoS One; 2021; 16(9):e0248222. PubMed ID: 34555031
[TBL] [Abstract][Full Text] [Related]
18. PF-05280014: A Trastuzumab Biosimilar.
Paik J
BioDrugs; 2018 Oct; 32(5):515-518. PubMed ID: 30280367
[TBL] [Abstract][Full Text] [Related]
19. A phase I dose-escalation and bioequivalence study of a trastuzumab biosimilar in healthy male volunteers.
Wisman LA; De Cock EP; Reijers JA; Kamerling IM; Van Os SH; de Kam ML; Burggraaf J; Voortman G
Clin Drug Investig; 2014 Dec; 34(12):887-94. PubMed ID: 25377592
[TBL] [Abstract][Full Text] [Related]
20. A randomized study comparing the pharmacokinetics of the potential biosimilar PF-06438179/GP1111 with Remicade® (infliximab) in healthy subjects (REFLECTIONS B537-01).
Palaparthy R; Udata C; Hua SY; Yin D; Cai CH; Salts S; Rehman MI; McClellan J; Meng X
Expert Rev Clin Immunol; 2018 Apr; 14(4):329-336. PubMed ID: 29504427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]